ArriVent BioPharma Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Apr '25 Apr 29, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Market Capitalization	714	898	-	-	-
Enterprise Value	493	615	-	-	-
Last Close Price	20.92	26.64	-	-	-
PB Ratio	2.74	3.48	-	-	-
P/TBV Ratio	2.76	3.48	-	-	-
Debt / Equity Ratio	0.00	0.00	0.00	0.00	-
Quick Ratio	12.70	12.70	13.00	19.60	20.64
Current Ratio	13.14	13.14	13.76	21.85	23.63
Return on Equity (ROE)	-39.36%	-39.36%	-42.57%	-34.22%	-
Return on Assets (ROA)	-26.91%	-26.91%	-26.95%	-20.42%	-
Return on Capital (ROIC)	-28.79%	-28.79%	-28.58%	-21.38%	-
Earnings Yield	-11.31%	-8.97%	-	-	-
Buyback Yield / Dilution	-1369.88%	-1369.88%	-67.64%	-79.57%	-

Updated Mar 3, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q